ATS Seeks Scleroderma Patients With Lung Disease to Take Survey

The American Thoracic Society (ATS) and the European Respiratory Society (ERS) seek scleroderma patients who have been diagnosed with lung disease (pulmonary fibrosis or pulmonary hypertension) to take a brief survey.

ATS/ERS developed this brief survey for patients with respiratory disease in order to seek patients' input into their knowledge of, access to, and experiences with pulmonary rehabilitation to help develop new policies in regards to its use. Despite the well-established evidence demonstrating the benefits of pulmonary rehabilitation for patients, the actual practice of pulmonary rehabilitation remains underutilized worldwide. The intention of this survey is to help bridge the gap between the science of pulmonary rehabilitation and the real world delivery of its services.

Click here to take the survey >>

Play an Active Role in Your Healthcare Through Clinical Trials

Clinical trials involve research using human volunteers intended to add to medical knowledge. Participants receive specific interventions that include medical products, such as drugs or devices, procedures, or changes to participants’ behavior. Clinical trials are at the heart of all medical advances because their purpose is to look at new ways to prevent, detect, or treat disease.

In a trial, researchers strive to determine if a new treatment is safe and effective.
Most patients diagnosed with scleroderma are young to middle-aged women. The disorder is characterized by local or widespread tightening of the skin, which may thicken and become hard and nodular. Changes in internal organs may also occur, including inflammation, fibrosis, and thickening of the vessel walls. The clinical manifestations of scleroderma vary among individuals, and personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader's physician(s) for proper evaluation and treatment.